Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | DHODH | Q02127 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25294798 | 0.89 | L3MBTL1 (0.68) | L3MBTL1ALDH1A1HPGDSMN1; SMN2RAB9A | |
| SCHEMBL20888390 | 0.85 | ALDH1A1 (0.70) | ALDH1A1HPGDSMN1; SMN2RAB9ATSHR | |
| SCHEMBL3046343 | 0.85 | ALDH1A1 (0.70) | ALDH1A1HPGDSMN1; SMN2RAB9ATSHR | |
| SCHEMBL7147053 | 0.84 | ALDH1A1 (0.74) | ALDH1A1HPGDSMN1; SMN2RAB9ATSHR | |
| SCHEMBL28720614 | 0.84 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1HPGDSMN1; SMN2RAB9A | |
| SCHEMBL8555317 | 0.83 | ALDH1A1 (0.76) | ALDH1A1HPGDSMN1; SMN2RAB9ATSHR | |
| SCHEMBL25251560 | 0.83 | ALDH1A1 (0.67) | ALDH1A1HPGDSMN1; SMN2RAB9ATSHR | |
| SCHEMBL12034449 | 0.82 | CDC7 (0.69) | ALDH1A1HPGDRAB9ATSHRNPC1 | |
| SCHEMBL28721473 | 0.81 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1HPGDSMN1; SMN2RAB9A | |
| SCHEMBL1540240 | 0.81 | ALDH1A1 (0.67) | ALDH1A1HPGDSMN1; SMN2RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | ALKAHEST, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-112010844-B | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| CN-114057666-B | Synthesis method of 4, 5-disubstituted-2-aminothiazole compound | 沈阳药科大学 | 2023-02-07 | — | — | CN | disclosed |
| CN-114057666-A | Synthesis method of 4, 5-disubstituted-2-aminothiazole compound | 沈阳药科大学 | 2022-02-18 | — | — | CN | disclosed |
| WO-2021155781-A1 | BENZENE SULFONAMIDE COMPOUND CONTAINING FIVE-MEMBERED HETEROCYCLE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2021-08-12 | — | — | WO | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-0639574-B1 | 2-aminothiazolecarboxamide derivatives, processes for their preparation and their use for controlling phytopathogenic organisms | LUCKY LTD (KR) | 1998-06-10 | — | — | EP | disclosed |
| US-5514643-A | FUNGICIDES FOR PLANTS | LUCKY LTD. (KR) | 1996-05-07 | — | — | US | disclosed |
| EP-0639574-A1 | 2-aminothiazolecarboxamide derivatives, processes for their preparation and their use for controlling phytopathogenic organisms | LUCKY LTD. (KR) | 1995-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | L3MBTL1 2054/4885ALDH1A1 1680/4885HPGD 204/4885 |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | L3MBTL1 4242/4885ALDH1A1 4741/4885HPGD 2874/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | L3MBTL1 2883/4885ALDH1A1 3361/4885HPGD 3417/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | L3MBTL1 3459/4885ALDH1A1 876/4885HPGD 3273/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | L3MBTL1 3434/4885ALDH1A1 664/4885HPGD 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.